Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority (EDA), held a meeting with representatives of EIPICO and the Indian company Reliance Life Sciences to enhance cooperation between the two sides and to advance pharmaceutical development in Egypt ensuring a qualitative leap in the pharmaceutical industry. The efforts of the two companies in supporting the pharmaceutical sector were also praised, especially with regard to the development of pharmaceutical preparations and support for innovation.
Dr. Ali El-Ghamrawy emphasized the importance of cooperation between national and international companies in order to facilitate knowledge transfer and the adoption of cutting-edge technologies. He also praised EIPICO's efforts in supporting the development of the pharmaceutical industry in Egypt, and commended Reliance's great efforts in the field of pharmaceutical research, and capability to develop and market numerous biosimilars globally.
The Chairman of the Authority affirmed that Egypt looks forward to further cooperation with Reliance and that the EDA is ready to provide all necessary technical and regulatory support, facilitate partnerships with local industry players, and streamline procedures to enhance market presence and competitiveness in the Egyptian pharmaceutical sector.
He also praised the strength of the Egyptian pharmaceutical market and its regional rise, noting that the sales volume of the pharmaceutical market reached 307 billion pounds last year, compared to sales of 216 billion pounds in 2023. Additionally, a total of 3.5 billion medicine packs were traded last year, compared to 3.7 billion packs in 2023.
The meeting was attended by Dr. Ahmed Kilani, Chairman of the Board of Directors of EIPICO, Dr. Marwan Suleiman, General Manager of the EIPICO, and Dr. Amal Abdel Khaleq, Manager of Regulatory Affairs and Pharmaceutical Vigilance at EIPICO, in addition to Mrs. Pranjali Prashant, Vice President of Reliance Life Science of India, and Mr. Ritesh Kumar, General Manager of the company's office in India, and from the leaders of the EDA, Dr. Asmaa Fouad, Head of the Central Administration of Biological and Innovative Products and Clinical Studies, and Dr. Osama Hatem, Associate Chairman of the Authority for Policies and International Cooperation and Supervisor of the Central Administration of Pharmaceutical Policies and Market Access.
The meeting comes within the framework of the EDA's strategy aimed at developing pharmaceutical policies and strengthening international partnerships, with the aim of improving the quality of health care for the Egyptian citizen and achieving a balance between the availability of medicines at appropriate prices and ensuring their quality and effectiveness.